CMB (CMB) News
Track canonical SquawkNews coverage tagged to CMB, CMB. This hub brings together deduplicated headlines about yhd, markets catalysts, earnings, analyst actions, and wider market events so traders can review how a developing story changed over time. It contains 2 indexed stories across 2 publication days and is ordered by the same first-publication timeline used by LiveCast.
M
Cambium Bio raises A$10.85m for Phase 3 dry eye trial
Strategic shareholders committed A$7.1m at a premium to market, and the company secured A$3.75m via non-dilutive R&D Tax Incentive pre-financing, funding Phase 3 of Elate Ocular® for dry eye disease.
EQUITY | Sep 16, 2026, 04:42 AM UTC
L
Cambium Bio announces change in company secretary
Cambium Bio announced a change in company secretary.
EQUITY | Aug 27, 2026, 01:38 AM UTC